Streptomyces griseoflavus

Streptomyces griseoflavus: An Encyclopedic Reference

1. Identity, Taxonomy, and Natural Source

Streptomyces griseoflavus is a Gram-positive, filamentous, spore-forming bacterium belonging to the domain Bacteria. Its full taxonomic lineage places it within the cellular organisms → Bacteria → Bacillati → Actinomycetota → Actinomycetes → Kitasatosporales → Streptomycetaceae → Streptomyces. At the species level it is formally designated Streptomyces griseoflavus (Krainsky 1914) Waksman & Henrici 1948. The species epithet and its standing name were published in the International Journal of Systematic Bacteriology (30:385). A recognized subspecies, Streptomyces griseoflavus subsp. pyrindicus, is also listed in the NCBI Taxonomy database.

Streptomyces griseoflavus is a bacterium species from the genus Streptomyces which has been isolated from garden soil. More broadly, the distribution of Streptomyces is shaped by a range of biological and physicochemical factors, leading to their presence in marine environments, soils, rhizospheres, animal excreta, and some endophytic contexts. Members of the genus are Gram-positive, filamentous, spore-forming bacteria that are members of the phylum Actinobacteria.

The organism exhibits the characteristic Streptomycete life cycle, forming branching aerial hyphae and chains of conidia (spores). Streptomyces is a genus of actinomycetes distinguished by its complex hyphal system and a high GC content in its genome. Its secondary metabolic capacity is substantial: streptomycetes are characterised by a complex secondary metabolism, with between 5–23% (average: 12%) of the protein-coding genes of each Streptomyces species implicated in secondary metabolism.

In the context of dietary supplements, S. griseoflavus appears as one of numerous soil-derived bacterial species included in multi-strain soil-based organism (SBO) probiotic preparations. One commercially marketed SBO probiotic formulation lists Streptomyces griseoflavus alongside other actinomycetes and soil bacteria, including Streptomyces fradiae, Streptomyces cellulosae, and a broad range of other soil-originating organisms. The preparation is presented in cellulose (vegetarian) capsules with l-leucine and bamboo extract as other ingredients, with a stated adult dosage of 1–2 capsules per day.

2. Historical and Traditional Context

There is no documented history of S. griseoflavus being used as a standalone traditional medicinal agent in any recorded ethnopharmacological tradition. The bacterium's scientific history begins with its isolation from soil by Krainsky in 1914 and formal renaming by Waksman and Henrici in 1948, consistent with how the broader genus was first scientifically classified.

The genus Streptomyces as a whole has a documented relationship with antibiotic discovery that began in the mid-twentieth century. Interest in the genus Streptomyces for antibiotics came after the discovery of the antibiotic streptomycin in a S. griseus strain in 1943. The discovery of streptomycin, an antituberculosis antibiotic, earned Selman Waksman the Nobel Prize in 1952. Waksman was credited with coining the term "antibiotic," winning the Nobel Prize for Medicine in 1952 and patenting eight antibiotics.

More recently, researchers have documented that soil bacteria closely related to S. griseoflavus—indeed, streptomycetes generally—have been found embedded within various traditional medicine practices around the world. Streptomyces currently provides many of the world's clinical antibiotics, so it comes as no surprise that these bacteria have recently been isolated from traditional medicine. Given the wide array of traditional medicines, it is hoped that these discoveries can provide the much sought-after core structure diversity required of a new generation of antibiotics. The relationship between traditional soil-based preparations (such as healing earths and clay poultices) and Streptomycete activity has been an active area of ethnopharmacological investigation, though no published sources attribute specific preparations to S. griseoflavus itself.

With respect to the concept of soil-based organisms as health-promoting agents, a theoretical basis has been proposed rooted in human evolutionary exposure. Streptomyces are in low abundance in mucosal microbiomes, with higher occurrence in non-humans that ingest soil than in humans. This phenomenon could be related to our current hygienic lifestyle, where soil particles adhering to raw food are washed off or sterilized by cooking before ingestion.

3. Key Constituents and Active Compounds

S. griseoflavus is a documented producer of several chemically distinct secondary metabolites. Streptomyces griseoflavus produces bicozamycin, colabomycins A, colabomycins C, germacradienol, and hormaomycin. Each of these compounds has a distinct chemical identity and biological profile.

3.1 Bicozamycin (Bicyclomycin)

Bicyclomycin (BCM) is a broad-spectrum antibiotic active against Gram-negative bacteria that was first isolated in 1972 from Streptomyces cinnamoneus and is also produced by other Streptomyces species, including S. griseoflavus. BCM (also known as bicozamycin) is one of the most complex members of the 2,5-diketopiperazine (DKP) family of molecules, which are cyclic dipeptides generated by the head-to-tail condensation of two α-amino acids.

The core DKP of BCM, cyclo(l-Ile-l-Leu), is modified with a characteristic second cycle that forms a [4.2.2] bicyclic unit, an exomethylene group, and multiple hydroxylations. Among the DKPs, bicyclomycin is a highly oxidized, clinically-relevant molecule with a unique mechanism of action.

Research into its biosynthesis in S. griseoflavus has illuminated how the organism regulates production of this metabolite at the cellular level. The high-producing strain was characterized by: an increased pool size of amino acids including leucine and isoleucine (precursors for bicozamycin synthesis), an earlier and greater accumulation of intracellular ppGpp, a more accentuated decrease in GTP pool size, a higher specific activity of ornithine transcarbamylase which produces citrulline, an increased ability to form aerial mycelium, and an increased resistance to its own antibiotic.

3.2 Hormaomycin (Takaokamycin)

Hormaomycin produced by Streptomyces griseoflavus is a structurally highly modified depsipeptide that contains several unique building blocks with cyclopropyl, nitro, and chlorine moieties. Within the genus Streptomyces, it acts as a bacterial hormone that induces morphological differentiation and the production of bioactive secondary metabolites. In addition, hormaomycin is an extremely potent narrow-spectrum antibiotic.

HRM, isolated from Streptomyces griseoflavus W-384, exhibits an extraordinary structure containing almost exclusively nonproteinogenic building blocks, several of which carry chloro, nitro, and cyclopropyl moieties. 3-(trans-2′-nitrocyclopropyl)alanine and 4-(Z)-propenylproline are unusual building blocks to HRM.

Its biosynthetic pathway is assembled by a nonribosomal peptide synthetase (NRPS) system. Biosynthesis has been illuminated by a combination of feeding studies, isolation of the biosynthetic NRPS gene cluster, and in vivo and in vitro functional analysis of enzymes. Several nonnatural hormaomycin congeners were generated by feeding-induced metabolic rerouting. The NRPS contains numerous highly repetitive regions that suggest an evolutionary scenario for this unusual bacterial hormone, providing new opportunities for evolution-inspired metabolic engineering of novel nonribosomal peptides.

Hormaomycin is also known as takaokamycin. An example of the biosynthetic sophistication found in this genus is the depsipeptide hormaomycin (HRM), also known as takaokamycin. Regulatory control of HRM production in S. griseoflavus W-384 involves cluster-situated regulatory genes. Cluster-situated regulatory genes hrmA and hrmB regulate hormaomycin production in Streptomyces griseoflavus W-384.

3.3 Germacradienol

S. griseoflavus also produces germacradienol, a sesquiterpene alcohol. The formation of germacradienol appears to be the committed step in the formation of geosmin, the characteristic odoriferous constituent of Streptomyces species. Germacradienol is therefore a metabolic intermediate rather than an end-product per se, representing a branch point in terpenoid secondary metabolism.

3.4 Colabomycins A and C

Streptomyces griseoflavus is documented as a producer of colabomycins A and C. These compounds belong to a group of bioactive metabolites characterised within Streptomyces secondary metabolism; however, the published peer-reviewed literature specifically characterizing their biological activity against human health targets is extremely limited, and no verified clinical data were identified in the available literature.

4. Mechanisms of Action of Key Metabolites

4.1 Mechanism of Bicozamycin

The mechanism of action of bicozamycin has been studied extensively at the molecular level. BCM is a selective inhibitor of the transcription termination factor Rho, which is an essential protein in many bacteria. The ability of bicyclomycin to disrupt the activity of the bacterial termination factor Rho has been used to treat enteropathogenic Escherichia coli that causes diarrhoea.

An additional mechanistic line of research has investigated whether BCM, as an inhibitor of the bacterial transcription terminator Rho, causes oxidative stress in Escherichia coli cells. BCM (also known as bicozamycin) is obtained from several Streptomyces species including S. griseoflavus. It displays toxicity against numerous Gram-negative bacteria, including E. coli, Salmonella, Enterobacter, Shigella, and Neisseria.

4.2 Mechanism of Hormaomycin

Hormaomycin (HRM) is a structurally remarkable peptide produced by Streptomyces griseoflavus W-384 that acts as a Streptomyces signaling metabolite and exhibits potent antibiotic activity against coryneform actinomycetes.

Hormaomycin displays three biological activities: First, it initiates the development of aerial mycelia in some Streptomyces strains (the mechanism responsible for this activity is unknown). Secondly, hormaomycin is effective in stimulating antibiotic production in different Streptomyces species—it is possible to obtain overproduction of a variety of antibiotics by the use of hormaomycin in fermentation processes. Thirdly, it inhibits the growth of some bacteria. The sensitive bacteria are restricted to coryneform taxa such as Arthrobacter and Corynebacterium, which are closely related to Streptomyces.

The potency of hormaomycin as an inter-microbial signaling molecule is remarkable: the cyclodepsipeptide hormaomycin, produced by Streptomyces griseoflavus, stimulates the production of antimicrobial secondary metabolites and the formation of aerial mycelium of various actinomycetes at nanomolar concentrations.

5. Scientific Evidence by Area of Use

Important prefatory note: S. griseoflavus is not studied directly in human clinical trials as a dietary supplement or probiotic agent. The scientific evidence below pertains to: (a) clinical evidence for its key metabolite bicozamycin (investigated as a pharmaceutical antibiotic), (b) microbiological and mechanistic evidence for hormaomycin and other metabolites (in vitro and preclinical only), and (c) genus-level evidence for Streptomyces as a probiotic taxon.

5.1 Bicozamycin in Traveler's Diarrhea (Clinical Evidence)

Evidence strength: Limited — older, non-replicated clinical data; drug not approved in the United States.

BCM has been used to treat traveler's diarrhea, as well as used as a veterinary medicine to treat fish, calves, and pigs.

One clinical prophylaxis study has been reported in the published literature. Administration of 500 mg of bicozamycin four times daily for 21 days, to adult US citizens traveling to Guadalajara, Mexico, showed high protection against traveler's diarrhea. However, resistance to bicozamycin was also detected in that study, and the drug was not further developed for human use.

Commentary from clinical review literature notes that bicozamycin has shown some benefit in the treatment of traveler's diarrhea as a nonabsorbable antimicrobial drug, and might be an effective prophylactic agent that would treat only the gastrointestinal tract and therefore be more acceptable from the standpoint of safety, though it was not marketed in the United States.

5.2 Hormaomycin: Preclinical and In Vitro Data Only

Evidence strength: Preclinical / in vitro only; no clinical human studies identified.

All published research on hormaomycin's biological activity is derived from in vitro microbiology experiments and mechanistic biochemistry. Its documented activities—inducing aerial mycelium formation, stimulating antibiotic biosynthesis in other streptomycetes, and narrow-spectrum antibacterial action against coryneform actinomycetes—are relevant to microbial ecology and biotechnology but have not been studied in animal models or human clinical trials in the context of supplementation or therapy.

5.3 Streptomyces Genus as Probiotics: Animal and Emerging Research

Evidence strength: Preliminary; predominantly animal/aquaculture data; no species-specific human clinical trials for S. griseoflavus.

Streptomyces have been used as probiotics in the aquaculture industry due to their production of antimicrobial substances against infectious diseases, secretion of exoenzymes facilitating feed utilization and digestion, and longer shelf life due to the formation of heat- and desiccation-resistant spores. Numerous trials suggest that Streptomyces have several positive effects in aquaculture, with particular reference to improvements in survival, growth rate, feed conversion efficiency, and prevention of intestinal infections.

Alterations in microbiome members and/or functions could occur after soil bacteria ingestion, leading to systemic changes in the immune response. Some researchers have reported that after ingestion, Streptomyces might be translocated to Peyer's patches (aggregated lymphoid nodules in gut tissue), producing positive changes in the immune system, such as expanding the repertoire of memory T lymphocytes. This remains a hypothesis supported only by limited non-human data.

Streptomyces are an essential group of soil bacteria in the Actinomycetes family. They are related to producing a wide range of secondary metabolites known for their beneficial effects on human health. However, according to human microbiome analysis, a lower prevalence of the Streptomyces genus exists than in other non-human microbiomes. This difference can be associated with current lifestyles.

No randomized controlled trials, systematic reviews, or meta-analyses specifically investigating S. griseoflavus as a dietary supplement in humans were identified in the peer-reviewed literature.

6. Body Systems and Health Areas of Association

• Gastrointestinal system: Bicozamycin's clinical application was specifically gastrointestinal, targeting enteric pathogens causing diarrhea. Its non-absorbable nature means activity is confined to the gut lumen. BCM is obtained from several Streptomyces species including S. griseoflavus and displays toxicity against numerous Gram-negative bacteria including E. coli, Salmonella, Enterobacter, Shigella, and Neisseria.
• Immune system: At the genus level, Streptomyces ingestion has been hypothesized to produce positive changes in the immune system, such as expanding the repertoire of memory T lymphocytes, via translocation to Peyer's patches. This applies broadly to the genus and has not been confirmed specifically for S. griseoflavus.
• Microbial ecology / Microbiome: The effect of a probiotic on gut microbiota depends not only on the species of microorganism but specifically on the strain. In human beings, specific probiotics have been associated with numerous beneficial properties, including weight modulation, immune modulation, and prevention of many disorders such as lactose intolerance, cardiovascular diseases, and antibiotic-associated diarrhoea. These associations are drawn from the broader probiotic literature and cannot be attributed specifically to S. griseoflavus without species-specific evidence.
• Antimicrobial / Anti-infective: The organism's produced metabolites are primarily of interest for antimicrobial applications. Streptomycetes produce over two-thirds of the clinically useful antibiotics of natural origin.

7. Dosage Forms and Reported Dosages

S. griseoflavus as a whole organism appears in multi-strain SBO probiotic capsule formulations. In at least one such commercially prepared SBO formulation, the recommended adult dosage is 1–2 capsules per day, or as directed by a healthcare professional. No controlled dosing studies for S. griseoflavus specifically as a dietary supplement have been published in peer-reviewed literature.

For bicozamycin, the dosage investigated in the principal human clinical study was 500 mg four times daily for 21 days in adult travelers. This dosing regimen pertains to the antibiotic compound as a pharmaceutical product, not to the organism itself.

8. Safety Considerations

Safety data specific to ingestion of whole S. griseoflavus as a dietary supplement in humans have not been published in peer-reviewed literature. The following considerations are drawn from documented evidence:

• Resistance development: Resistance to bicozamycin has been detected in clinical use, and the drug was not further developed for human pharmaceutical use. This resistance was a limiting factor in the antibiotic's development.
• Narrow-spectrum antimicrobial activity: Hormaomycin produced by S. griseoflavus is described as a potent but narrow-spectrum antibiotic active principally against coryneform actinomycetes. The sensitive bacteria are restricted to coryneform taxa such as Arthrobacter and Corynebacterium, which are closely related to Streptomyces.
• Spore-forming nature: S. griseoflavus, as a member of the genus Streptomyces, can form spores. A key characteristic of many soil-based organisms is that they are spore-forming. When conditions are less favorable, these organisms can form a small spore—a dormant form with a hard, protective outer coating—that is highly resistant to heat, acid, and most antibiotics. This characteristic raises questions about persistence and unpredictability of effects in the gastrointestinal tract, though no specific adverse events have been documented in the published literature for S. griseoflavus in this context.
• Genus-level pathogenicity note: Streptomycetes are infrequent pathogens, though infections in humans (actinomycetoma) can be caused by S. somaliensis and S. sudanensis. S. griseoflavus is not listed among documented human pathogens in the peer-reviewed literature.
• Strain-specificity of probiotic effects: The effect of a probiotic on gut microbiota depends not only on the species of microorganism but specifically on the strain. Safety and efficacy inferences cannot be reliably extrapolated across strains within S. griseoflavus or from other Streptomyces species.
• Absence of clinical trial data: No published Phase I, II, or III human clinical trials evaluating the safety or tolerability of S. griseoflavus as a probiotic supplement were identified in the available peer-reviewed or regulatory literature. This represents a fundamental gap in the safety evidence base.

9. Evidence Characterization Summary

The scientific literature on Streptomyces griseoflavus is primarily concentrated in the fields of microbiology, natural products chemistry, and pharmaceutical antibiotic research. Its key metabolites—bicozamycin and hormaomycin—have been characterized at the molecular and mechanistic level in peer-reviewed studies. Bicozamycin has limited clinical data in traveler's diarrhea prophylaxis (one reported study; the compound was not approved or further developed for human pharmaceutical use). Hormaomycin has been studied exclusively in microbial systems.

As a dietary supplement or probiotic ingredient, S. griseoflavus occupies a position as one constituent among many in multi-strain SBO preparations. No species-specific human clinical trials exist. Genus-level evidence for Streptomyces in human health is early-stage, primarily from animal and aquaculture models, and the clinical relevance to human supplementation has not been established by controlled trials.

References

• Wikipedia — Streptomyces griseoflavus
• NCBI Taxonomy Browser — Streptomyces griseoflavus
• GBIF Backbone Taxonomy — Streptomyces griseoflavus (Krainsky, 1914) Waksman & Henrici, 1948
• Wikipedia — Streptomyces (genus overview)
• PMC — Bicyclomycin generates ROS and blocks cell division in Escherichia coli (PLOS One, 2024)
• PMC — Discovery and Biosynthesis of the Antibiotic Bicyclomycin in Distantly Related Bacterial Classes
• Scientific Reports — Study of bicyclomycin biosynthesis in Streptomyces cinnamoneus by genetic and biochemical approaches (2019)
• PubMed — Restoration of aerial mycelium and antibiotic production in a Streptomyces griseoflavus arginine auxotroph (J Gen Microbiol, 1984)
• PubMed — Physiological analysis of bicozamycin high-producing Streptomyces griseoflavus used at industrial level
• De Gruyter — Hormaomycin, a New Peptide Lactone Antibiotic Effective in Inducing Cytodifferentiation and Antibiotic Biosynthesis in Some Streptomyces Species (1990)
• PubMed — Manipulation of Regulatory Genes Reveals Complexity and Fidelity in Hormaomycin Biosynthesis (Chemistry & Biology, 2013)
• ScienceDirect — Insights into the Biosynthesis of Hormaomycin, An Exceptionally Complex Bacterial Signaling Metabolite (Chemistry & Biology, 2011)
• PMC — Expression and mechanistic analysis of a germacradienol synthase from Streptomyces coelicolor implicated in geosmin biosynthesis
• PMC — Streptomyces from traditional medicine: sources of new innovations in antibiotic discovery (J Med Microbiol, 2020)
• ScienceDirect — Streptomyces genus as a source of probiotics and its potential for its use in health (2022)
• PMC — A review of antibiotic prophylaxis for traveler's diarrhea: past to present (Tropical Diseases, Travel Medicine and Vaccines, 2018)
• American Academy of Family Physicians — Prevention and Treatment of Traveler's Diarrhea (Am Fam Physician, 1999)
• PMC — Streptomyces flavusporus sp. nov., a Novel Actinomycete Isolated from Naidong, Xizang (Tibet), China (2025)
• Wikipedia — Streptomyces griseus